Aurinia Pharmaceuticals (AUPH) Cost of Revenue (2021 - 2026)

Aurinia Pharmaceuticals (AUPH) has 6 years of Cost of Revenue data on file, last reported at $6.5 million in Q1 2026.

• Quarterly Cost of Revenue fell 24.13% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.6 million (up 5.25% YoY) and the FY2025 annual result came in at $32.7 million, up 15.64% from the prior year.
• Cost of Revenue retreated to $6.5 million in Q1 2026, from $8.8 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $8.9 million in Q2 2024 to a low of $256000.0 in Q1 2022.
• A 5-year average of $5.1 million and a median of $6.0 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2024 — Cost of Revenue soared 1741.33% — and 2026, when it slipped 24.13%.
• Tracing AUPH's Cost of Revenue over 5 years: stood at $1.4 million in 2022, then jumped by 296.11% to $5.4 million in 2023, then rose by 2.91% to $5.6 million in 2024, then soared by 58.48% to $8.8 million in 2025, then decreased by 26.07% to $6.5 million in 2026.
• The last three Cost of Revenue figures came in at $6.5 million (Q1 2026), $8.8 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.